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Background: Iliac vein stenting technology is rapidly emerging as a minimally invasive alternative to traditional open
venovenous bypass procedures for iliac vein stenoses and chronic total occlusions.
Methods: Peer-reviewed publications meeting eligibility criteria were retrieved and reviewed from public domain databases.
Results: Reviewed reports encompass w1500 patients. Evidence quality was judged moderate, with a grade 1B recom-
mendation (beneﬁts outweigh risks) for patients with disabling symptoms in whom conservative therapy had failed. A
grade 2B recommendation was assigned for patients with less severe symptoms. Iliac vein stenting is safe, with negligible
morbidity (<1%). Patency was 90% to 100% for nonthrombotic disease and 74% to 89% for post-thrombotic disease at 3
to 5 years. Clinical relief of pain was 86% to 94%, and relief from swelling was 66% to 89%. From 58% to 89% of venous
ulcers healed. Procedural success in recanalization of chronic total occlusions was 83% to 95%. Hybrid techniques for
complex cases are in evolution.
Conclusions: Iliac vein stenting is emerging as a safe and effective alternative to traditional open surgery to correct iliac vein
obstruction. (J Vasc Surg 2013;57:1163-9.)Venous stent technology has rapidly evolved as the
initial procedure of choice in the treatment of iliofemoral
stenosis and chronic total occlusions (CTO). Open
surgery, the prior standard, is now reserved only for stent
failures. Concurrently, the use of intravascular ultrasound
(IVUS) imaging, essential for proper stent placement, has
broadened the scope of stent treatment to include primary
nonthrombotic iliac vein lesions (NIVL). Previously,
obstruction in this genre was thought to be relatively
rare, largely due to the poor diagnostic sensitivity of
venography.
The pivotal role of iliac vein stenoses as a cause of recur-
rent thrombosis and in the development of post-thrombotic
syndrome (PTS) is now well recognized. Clinical relief,
including ulcer healing, occurs with iliac vein stenting even
in the presence of signiﬁcant reﬂux, an intriguing ﬁnding
with fundamental pathophysiologic implications.
Iliac vein stenting appears to be safe and effective, as
reviewed below; the technique is easier to learn and use
than open surgery, potentially beneﬁtting a larger propor-
tion of patients. Because open surgery is not precludedThe Rane Center for Venous and Lymphatic Disease.
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traditional venous bypass techniques, and strict efﬁcacy
comparisons are moot in a disease that seldom poses
a threat to limb or life. Accordingly, this evidence review
focuses on the iliac vein stent literature, and some key refer-
ences to open procedures are included to provide context.
METHODS
Peer reviewed articles in English were retrieved from
public domain databases with the following search terms:
“common iliac vein; iliac vein; iliofemoral vein; stenosis;
venous occlusion; postthrombotic syndrome; May-
Thurner syndrome; Cockett syndrome; iliac vaso compres-
sion syndrome,” and “venous stent.” All were listed in
Medline. The voluminous literature dealing with acute
occlusions was excluded because disease progression is
likely different. For outcome analysis, a selection threshold
of at least 25 limbs treated for chronic occlusions with
a minimum follow-up of 3 years was applied. None that
met the threshold were excluded; some below the
threshold and ancillary references have been selectively
included to highlight special features of interest.
RESULTS
All studies reviewed are single-arm retrospective case
series. The quality of evidence1 for stent treatment was
graded as moderate. The consistency of the evidence and
the magnitude of effects, such as ulcer healing, for example,
suggest a grade 1B recommendation (strong recommenda-
tion, beneﬁts outweigh risks) for patients with disabling
symptoms in whom conservative therapy has failed.
Complex surgical procedures, such as venovenous bypass1163
Table I. Incidence and diagnosis of iliac vein obstruction
First author, year Comments
Negus,5 1967 Exercise femoral pressure parameters to
diagnose iliac vein obstruction
Negus,6 1968 Poor sensitivity of venography; incidence in
general population
Thomas,7 1967 Technique of iliac venography; description of
collaterals
Raju,8 2011 Poor sensitivity of venography; diagnostic
accuracy with combination of techniques
Hurst,9 2001 Use of IVUS for the diagnosis of iliac vein
obstruction
Neglen,10 2002 Superiority of IVUS imaging over venography
for diagnosis
Forauer,11 2002 IVUS guidance essential for proper stent
placement
Raju,4 2006 IVUS imaging features of thrombotic and
nonthrombotic lesions. High prevalence of
the lesion in nonthrombotic disease
Marston,12 2011 Sensitivity of MR and CT imaging to detect
iliac vein obstruction
Kibbe,13 2004 Frequent prevalence of the lesion (CT) in
silent form in the general population
CT, computed tomography; IVUS, intravascular ultrasound; MR, magnetic
resonance.
Table II. Techniques of correcting iliac vein obstruction
First author, year Comments
Halliday,17 1985 Palma bypass; 47 PTS limbs. Venographic
cumulative patency of 75% at 5 years
Jost,18 2001 18 Palma bypass
d 17 prosthetic bypass
d 6 spiral vein bypass
d 1 vein patch
d 62% overall cumulative patency at
3 years and 83% for Palma bypass at
4 years
Puggioni,19 2004 Technique of endophlebectomy
Garg,20 2011 Hybrid and open techniques of correction
Neglen,21-25
2000-2010
Technique of iliac vein stenting; need for
large stents and extension into inferior
vena cava. Stent extension across inguinal
ligament. Bilateral iliac vein stents.
Stenting across stenotic/occluded IVC
ﬁlters. Incidence of ISR after iliac vein
stent
Raju,26 2009 CTO recanalization technique
Kolbel,27 2009 Jugular approach for CTO recanalization;
ancillary techniques
Raju,28 2009 Different types of stent malfunction and
reinterventional techniques to correct
them
CTO, Chronic total occlusions; ISR, in-stent restenosis; IVC, inferior vena
cava; PTS, post-thrombotic stenosis.
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options for such patients before. A grade 2B recommenda-
tion was assigned for patients with less severe symptoms.
Clinical features and pathophysiology
Symptomatic iliac-caval obstruction of NIVL or PTS
etiology can present with a wide range of clinical features,
including all clinical CEAP classes. Speciﬁc correction is
seldom warranted unless advanced symptoms (CEAP clin-
ical class $3 or signiﬁcant pain). Orthostatic limb pain is
a pervasive feature but may be absent in w20% to 30% of
patients; it may be the only clinical manifestation sans other
clinical features in 10% to 15% of patients (CEAP #2).
Excellent pain relief may be obtained by stent treatment.2
Recurrent cellulitis, especially the spontaneous variety,
may be indicative of an underlying iliac obstructive lesion
amenable to correction and relief.3 Iliac vein thrombosis
secondary to an obstructive lesion is well known, with a vol-
uminous literature that is not reviewed here.
A confusing feature is the presence of iliac caval
pathology in a wide swath of the general population in
silent form. This has been a source of controversy in attrib-
uting pathologic signiﬁcance to a ubiquitous lesion. A
possible explanation to connect progression of a silent
lesion into a symptomatic one is the concept that the lesion
functions in a permissive fashion.4 Regardless, there is little
doubt that correction of iliac stenosis remits symptoms if
they occur.
Diagnosis
Diagnosis of iliac-caval obstruction remains hobbled by
the relative insensitivity of contrast venography (Table I).
This is because many iliac vein lesions are visible only in
one plane and membranous lesions may not be visible atall. Perivenous and wall ﬁbrosis are impervious to venog-
raphy; diffuse long stenoses common in post-thrombotic
disease are easily missed. Computed tomography or
magnetic resonance imaging techniques may have similar
sensitivity issues,12 but comparative studies to assess diag-
nostic accuracy are as yet unavailable.
Intravascular ultrasound (IVUS) imaging has emerged
as a promising new diagnostic tool with apparently higher
sensitivity and greater diagnostic yield (Table I). Previ-
ously, symptomatic NIVL incidence was thought to be
relatively rare, with w3% of the population with chronic
venous disease involving predominantly the left lower
limb of young women. Use of IVUS imaging has shown
that iliac-caval obstructions occur as commonly in non-
thrombotic cases as in post-thrombotic limbs, affecting
both sexes, all age groups, and both sides.
This lesion, ﬁrst described by McMurrich in 1908, was
more clearly deﬁned by several authors, notably by May
and Thurner (1957) and later Cockett (1965-1967).
Earlier autopsy studies14 and current IVUS ﬁndings clearly
indicate that NIVL are complex lesions involving not only
external compression but also wall ﬁbrosis, intraluminal
webs, and membranes. The term “iliac compression
syndrome” is, therefore, a misnomer.
The lesion is clearly nonthrombotic because it lacks the
pathognomic vascular invasion. A traumatic etiology from
pulsations of the intimately related artery is probably the
major cause, although an ontogenic origin is likely in
some, because the lesions, particularly membranous ones,
occur at embryologic fusion planes.14,15 The lesion has
Table III. Technical outcome of iliac vein stenting
First author
Limbs,
No. (%)
Case mix
NIVL/PTS,
No. (%)
Cumulative patency
Duration
cumulative
f/u, years
Complications
(No. of limbs) RemarksPrimary
Primary
assisted Assisted
Open and hybrid (with stent) reconstruction
Garg,20 2011 68 NIVL,
5/68 (7)
42% 47% 59% 5 Superﬁcial wound
infection (2)
Stenting below
inguinal ligament
increased stent
patency in hybrid
reconstructions
52 open PTS:
63/68 (93)
Lymphocele (3)
12 hybrid Wound hematoma
(2)
No death
No PE
Stent
Gutzeit,29 2011 15 Iatrogenic:
6/15 (40)
100% 100% 100% 22 Stent fracture (1)
with patency
Up to 22-year f/u
with no occlusions
in 15/20 with
f/up
PTS,
9/15 (60)
14 mean
Hartung,30 2009 89 NIVL:
52/89 (58)
83% 89% 93% 7 2 stent migrations 93% technical success
in CTO
30/89 (34)
CTO
PTS:
35/89 (39)
2 access site
hematomas
No PE
Congenital:
2/89 (3)
1 femoral artery tear CFV involvement
and post-
thrombotic disease
decreased patency
2 contrast
extravasation in
CTO
Reintervention in 8%
Unrelated death (1) Thrombophilia in
20% did not affect
patency
DVT (5)
Knipp,31 2007 58 PTS:
52/58 (90)
38% 63% 74% 5 1 retained balloon 58 stent procedures,
17% with recent
thrombus; recent
trauma, male sex
and age <40 years
decreased patency
which decreased
from 63% at 5
years to 29% and
0% for $2 risk
factors,
respectively
NIVL:
6/58 (10)
1 stent migration Thrombophilia in 19
did not affect
patency
1 groin hematoma
1 retroperitoneal
hematoma
Meng,32 2011 272 NIVL:
272/272 (100)
94% NA NA 5 Type of stent used
not mentioned
Neglen,2 2007 982 NIVL:
518/982 (53)
NIVL:
79%
100% 100% 6 4 femoral artery
injury
Thrombophilia in
38% did not affect
patency
PTS:
464/982 (47)
PTS:
57%
80% 86% 1 guidewire trapped
in stent
Ambulatory venous
pressure and
hand/foot
pressure improved
1.5% DVT/stent
thrombosis <30
days post-op
ISR (>50%)
occurred in 10% in
PTS and 1% in
NIVL at 6 years
3% DVT/stent
thrombosis >30
days post-op
No mortality
No pulmonary
embolus
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Table III. Continued.
First author
Limbs,
No. (%)
Case mix
NIVL/PTS,
No. (%)
Cumulative patency
Duration
cumulative
f/u, years
Complications
(No. of limbs) RemarksPrimary
Primary
assisted Assisted
Ye,33 2012 224 NIVL: 100% 99% 99% 99% 4 Local stent migration
(3)
Back pain (34)
No mortality
No DVT or PE
Recanalization of CTO
Kolbel,27 2009 59 PTS: 66% 67% 75% 79% 5 1 access-site bleed Technical success
95%
Other: 34% 2 perforations
requiring
transfusion
Stented below
inguinal. Ligament
in 70% did not
affect outcome
No PE Thrombophilia in
67% did not affect
patency
Raju,26 2009 139 PTS: 100% 32% 58% 66% 4 Back pain: 25% 83% technical success
1 transient rise in
contrast-related
creatinine
14 across IVC ﬁlters
did not affect
patency
DVT/stent
thrombosis <30
days: 10/139 (7)
Thrombophilia in
34% did not affect
patency
DVT/stent
thrombosis >30
days: 32/139 (23)
No bleeding
complications
including in stents
across IVC ﬁlters
Rosales,34 2010 34 PTS: 100% 67% 76% 90% 7 DVT: 11/34 (32) 94% technical success
65% stented below
inguinal ligament
Thrombophilia did
not affect patency
CTO, Chronic total occlusion; DVT, deep venous thrombosis; f/u, follow-up; ISR, in-stent restenosis; IVC, inferior vena cava; NA, not available; NIVL,
nonthrombotic iliac vein lesions; PE, pulmonary embolus; PTS, post-thrombotic syndrome.
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peritoneal ﬁbrosis, tumor, and other extrinsic causes of iliac
vein obstruction are relatively rare, accounting for w5% of
cases.
Treatment options
A variety of open, closed, and hybrid techniques are
now available for treating iliac vein obstructions (Table II).
Evidence summary
Technical outcome of iliac vein stenting. Stent treat-
ment appears to be a safe procedure. Among the w1500
patients in the series reviewed, no deaths or pulmonary
embolus were reported. Access site complications occurred
in <1% and signiﬁcant bleeding requiring transfusions
in <0.03%. The incidence of postoperative and interval
long-term deep venous thrombosis appears to be no
different from the incidence of native disease. Stent-related
complications, such as stent fracture, erosions, late embo-
lization, and infections, are extremely rare. It is not clear ifthis is related to the speciﬁc type of stent used. All of the
reviewed series, except one (information missing), reported
using self-expanding large-caliber Wallstents (Boston
Scientiﬁc, Natick, Mass) in most of the patients. Other
complications, such as back pain, occur early after the
procedure and are generally minor and self-limited.
Stent patency (Table III) has been surprisingly good,
considering the propensity for thrombosis in the venous
system with low velocity ﬂow. Stent thrombosis is an
extreme rarity in NIVL disease as reported, an astonishing
statistic considering arterial stent experience. Approxi-
mately 25% of stents occlude in thrombotic cases during
a 3- to 5-year period. Secondary patency has ranged from
90% to 100% in NIVL limbs and from 74% to 89% in
post-thrombotic limbs during 4 to 7 years. Patency is
somewhat lower, at 66% to 89% at 4 to 7 years, and stent
occlusions higher in the group among CTO recanaliza-
tions. Factors associated with stent occlusion include prior
thrombosis, male sex, recent trauma, and age <40 years,
with a combination of factors exponentially decreasing
Table IV. Clinical outcome of corrective procedures for iliac vein obstruction
First author, year Limbs CEAP
Ancillary
procedures
Clinical
outcome
Follow-up,
months Comments
Open surgical correction (venovenous bypass)
Jost,18 2001 42 C0: 10% Moderate
Improvement in
outcome score with
patent grafts. 7/9
ulcers healed
72 .
C2: 2%
C3: 45%
C4: 10%
C5: 12%
C6: 21%
Open and hybrid (with stent) reconstruction
Garg,20 2011 64 C0-2: 2 60% no pain & no or
minimal swelling
Median: 41
C3: 30 50% ulcer healing
C4: 12
C5: 8
C6: 12
Stent correction
Gutzeit,29 2011 15 Thigh size normalized Mean: 168
Hartung,30 2009 89 C2: 15 3 ovarian vein
embolization
43/45 improvement
in pain; in 31
complete relief
Median: 38
C3: 59 5 superﬁcial vein
procedures
5/6 (83%) ulcers
healed
C4: 7 23/26 pelvic
congestion
improved; 15 cured
C5: 2
C6: 6
Knipp,31 2007 63 C3: 47 28 thrombolysis Signiﬁcant clinical
improvement in
80%; no change in
20%
Mean: 30 Mix of acute and
chronic cases
C4: 12 6 AV ﬁstula
C5/C6: 4 18 IVC ﬁlters
Meng,32 2011 296 C2: 55 170 saphenous vein
high ligation and
stripping
Resolution of
swelling: 84%
Median: 46
272/296 stented C3: 238 24/296 POBA only 87% with skin
pigmentation
showed
improvement
C4: 133 85% ulcers healed
C5: 11
C6: 78
Neglen,2 2007 982 C2: 7% 197 GSV/SSV
ablations
Severe leg pain (VAS
>5) decreased from
54% to 11%;
cumulative total
relief of pain in 62%
Cumulative:
60
Symptom relief
reported on
cumulative basis
C3: 47% Severe swelling (grade
3) decreased from
44% to 18%;
cumulative total
relief of swelling in
32%
C4: 24% 58% (cumulative) of
ulcers healed
C5: 5% Signiﬁcant QOL
improvement in all
categories
C6: 17%
Ye,33 2012 224 C0: 5% 132/224 (59%)
EVLA
Edema relief: 89% Mean: 50
C1: 1% Ulcer healing: 82%
C2: 3% Pain decreased from
4.3 to 0.4 (VAS)
C3: 37% QOL signiﬁcantly
improved
C4: 12%
C5: 15%
C6: 28%
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Table IV. Continued.
First author, year Limbs CEAP
Ancillary
procedures
Clinical
outcome
Follow-up,
months Comments
Recanalization of CTO
Kolbel,27 2009 66 C3: 22 23% asymptomatic Median: 32 Thrombophilia did
not affect outcomeC4: 17 52% improved
C5: 12 20% same
C6: 8 6% worse
Raju,26 2009 139 C2: 3 Cumulative
improvement in
pain: 79%;
complete relief in
67%
Median: 48
C3: 71 Cumulative
improvement in
swelling: 66%
C4a: 14 Cumulative healing of
ulcers: 56%;
complete relief in
32%
C4b: 8 58% of ulcers healed
C5: 11 QOL signiﬁcantly
improved
C6: 32
Rosales,34 2010 34 C3: 27 Swelling and pain was
resolved in 32/34
(94)
Median: 33 Thrombophilia did
not affect outcome
C6: 7 4/7 (57) ulcers
healed
AV, Arteriovenous; GSV, great saphenous vein; IVC, inferior vena cava; QOL, quality of life; SSV, small saphenous vein; VAS, visual analog scale.
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outcome in several series. Technical success of CTO recan-
alizations has ranged from 83% to 95%.
Mild in-stent restenosis (ISR) is common, but signiﬁ-
cant lesions ($50%) occur in w10% of post-thrombotic
cases; it is extremely rare in the NIVL subset (1%). ISR
incidence is related to thrombophilia, prior thrombosis,
and use of a long stent.21 Limited experience indicates
that pregnancy can be tolerated after placement of self-
expanding stents.35
Use of anticoagulation during and after stent place-
ment has varied. Although some authors have used postop-
erative warfarin anticoagulation for several months after the
procedure, it does not seem to be necessary in NIVL.2,30,31
Patency rates appear not to be affected with use of only
aspirin after stent placement in this subset.
Clinical outcome. Clinical relief has been good to
excellent, as reported, and the results appear to be durable
(Table IV). Relief of pain is excellent, ranging from 86% to
94%, with total relief in most. Swelling relief is good,
ranging from 66% to 89%. Interestingly, ulcer healing
occurs in 58% to 89% of patients after stent placement,
even without correction of associated reﬂux.36,37 Two of
the larger series reported improvement in quality of life
parameters.
Iliac vein stents have been placed in stenosed or
occluded iliac veins to maintain dialysis access and in pedi-
atric patients with congenital heart defects to gain access
for catheterization.38 Iliac vein occlusion may lead toneurogenic claudication due to collateral congestion in the
spinal canal affecting the cord or cauda equina; diagnosis is
made with magnetic resonance or computed tomography
imaging. Relief with iliac vein stenting has been reported.39
One reviewed series30 reported relief of pelvic congestion in
a large subset after iliac vein stent placement.
Areas needing further study. Many areas related to
iliac vein stenting require further study and clariﬁcation,
including the role of IVUS imaging (used in only two
studies), the degree of correctible stenosis, the relation-
ship between silent and symptomatic obstructions, inter-
relationship of obstruction and reﬂux, and ﬁnally,
a hemodynamic metric for obstruction.
CONCLUSIONS
Stent placement to correct iliac-caval-femoral obstruc-
tions is emerging as a safe, effective, and minimally invasive
alternative to traditional open surgery.
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